Methoden vergelijken
Bekijk de geselecteerde methoden naast elkaar; rijen die verschillen zijn gemarkeerd.
| Doelwitgemedieerde Geneesmiddeldispositie× | Michaelis-Menten Kinetiek× | |
|---|---|---|
| Vakgebied | Farmacologie | Farmacologie |
| Familie | Process / pipeline | Process / pipeline |
| Jaar van ontstaan≠ | 2001 | 1913 |
| Grondlegger≠ | Donald Mager and William Jusko | Leonor Michaelis and Maud Menten |
| Type≠ | nonlinear PK modeling | mechanistic model |
| Oorspronkelijke bron≠ | Mager, D. E., & Jusko, W. J. (2001). General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics, 28(6), 507-532. DOI ↗ | Michaelis, L., & Menten, M. L. (1913). Die Kinetik der Invertinwirkung. Biochemische Zeitschrift, 49, 333-369. link ↗ |
| Aliassen≠ | TMDD, target-driven clearance | MM kinetics, Michaelis constant, Vmax |
| Verwant≠ | 3 | 2 |
| Samenvatting≠ | Target-mediated drug disposition (TMDD) is a mechanistic framework describing nonlinear pharmacokinetics arising from drug binding to a target receptor or protein. Developed by Mager and Jusko in 2001, TMDD explains saturable clearance, dose-dependent half-lives, and time-dependent changes in plasma concentrations observed with protein therapeutics and some small-molecule drugs. | Michaelis-Menten kinetics describes the rate of enzyme-catalyzed reactions as a function of substrate concentration. Developed by Leonor Michaelis and Maud Menten in 1913, this foundational framework models enzyme catalysis through the rapid-equilibrium approximation and enables prediction of drug metabolism rates in pharmacokinetics. |
| ScholarGateGegevensset ↗ |
|
|